BeyondSpring Files 2019 Annual Report on Form 20-F
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.About BeyondSpringBeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring’s lead asset, first in class agent Plinabulin as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.Contact:Media & Investor Relations :
Jeffrey Goldberger / Caitlin Kasunich
KCSA Strategic Communications
212.896.1249 / 212.896.1241
jgoldberger@kcsa.com / ckasunich@kcsa.com